Corbus Pharmaceuticals Holdings Inc represents values of integrity, innovation, and dedication to improving patient outcomes. With a strong corporate philosophy centered around developing groundbreaking therapies for inflammatory and fibrotic diseases, Corbus Pharmaceuticals is committed to advancing medical science and making a positive impact in the healthcare industry. Through their research and development efforts, the company strives to provide effective and safe treatment options for patients worldwide. Corbus Pharmaceuticals Holdings Inc's unwavering commitment to excellence and their focus on delivering high-quality healthcare solutions make them a trusted name in the pharmaceutical industry.

Corbus Pharmaceuticals Holdings Inc is primarily present in the United States.

Corbus Pharmaceuticals Holdings Inc, a renowned pharmaceutical company, has achieved several significant milestones. One notable accomplishment was the successful completion of its Phase 2 clinical trial for lenabasum, its lead drug candidate, in the treatment of systemic sclerosis. The company also reached a major milestone by receiving Fast Track designation from the U.S. FDA for lenabasum in the treatment of dermatomyositis. Additionally, Corbus Pharmaceuticals initiated a Phase 3 clinical trial for its potential treatment in cystic fibrosis, highlighting their commitment to advancing innovative therapies. With these achievements, Corbus Pharmaceuticals continues to demonstrate its dedication to improving patients' lives through groundbreaking research and development.

Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company founded in 2009. Headquartered in Norwood, Massachusetts, the company focuses on developing and commercializing innovative drugs to treat inflammatory and fibrotic diseases. Corbus Pharmaceuticals is dedicated to improving the lives of patients with rare, chronic, and severe diseases. With a strong emphasis on research and development, the company has pioneered a unique drug development platform targeting the endocannabinoid system. Through its novel drug candidates, including lenabasum, Corbus Pharmaceuticals aims to address unmet medical needs and provide promising treatment options for patients worldwide.

The main competitors of Corbus Pharmaceuticals Holdings Inc in the market include pharmaceutical companies such as Gilead Sciences Inc, AbbVie Inc, and Amgen Inc.

Corbus Pharmaceuticals Holdings Inc primarily operates in the biotechnology and pharmaceutical industries.

The business model of Corbus Pharmaceuticals Holdings Inc is focused on the development and commercialization of innovative therapeutics to address unmet medical needs. The company primarily focuses on developing therapies that target inflammatory and fibrotic diseases. Corbus Pharmaceuticals aims to provide effective treatment options for patients suffering from serious conditions such as systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus, among others. By leveraging its expertise in drug discovery and development, Corbus Pharmaceuticals aims to bring novel treatments to market that can improve patients' quality of life and potentially reshape the standard of care in these therapeutic areas.

Az Corbus Pharmaceuticals Holdings P/E mutatója -1,87.

Az Corbus Pharmaceuticals Holdings KUV 0.

Az AlleAktien Minőségi Score Corbus Pharmaceuticals Holdings esetében 5/10.

A Corbus Pharmaceuticals Holdings esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Corbus Pharmaceuticals Holdings nyereség -44,43 Mió. USD.

Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company specializing in the development and marketing of novel medications for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and has been listed on NASDAQ since 2014. The company focuses on developing medications based on cannabinoids, specifically targeting the CB2 receptor. The CB2 receptor plays an important role in regulating the immune system and is a promising target for the treatment of inflammation and fibrotic diseases. Corbus has developed its own technology platform to identify and develop highly selective and highly effective CB2 agonists. Corbus Pharmaceuticals' extensive portfolio currently includes multiple clinical phase 3 programs and clinical phase 2 programs in various indications, including the rare fibrotic disease idiopathic pulmonary fibrosis, systemic sclerosis, and dermatomyositis. In addition, the company is also developing medications for the treatment of other inflammatory and fibrotic diseases, including rheumatoid arthritis and cystic fibrosis. Corbus follows an integrated business model that focuses on internal research and development, as well as collaboration with strategic partners and acquisitions. The company has formed several partnerships with renowned academic institutions and scientists to expand and diversify its portfolio. Currently, the company does not offer any direct product offerings as all medications are still in the developmental phase. However, Corbus works closely with regulatory authorities and approval bodies to obtain market approvals for its medications in order to help patients as soon as possible. In doing so, the company aims to establish a strong market position in a highly dynamic and promising segment of the biopharmaceutical industry. So far, the results are promising, and the company sees good opportunities to address the underlying inflammatory and fibrotic diseases. Overall, Corbus Pharmaceuticals is an innovative biopharmaceutical company with a promising portfolio of potential therapeutics. The company relies on solid internal R&D development, as well as strategic collaboration with renowned academic institutions to expand its portfolio. Corbus aims to develop medications that positively impact the lives of patients with inflammatory and fibrotic diseases and improve the underlying disease mechanisms.

A(z) Corbus Pharmaceuticals Holdings évente alkalommal oszt ki 0 USD összegű osztalékot.

A Corbus Pharmaceuticals Holdings esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Corbus Pharmaceuticals Holdings ISIN kódja: US21833P1030.

A Corbus Pharmaceuticals Holdings WKN-je A14R7P.

Az Corbus Pharmaceuticals Holdings tőzsdei rövidítése CRBP.

Az elmúlt 12 hónapban a(z) Corbus Pharmaceuticals Holdings osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Corbus Pharmaceuticals Holdings várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Corbus Pharmaceuticals Holdings jelenlegi osztalékhozama .

A(z) Corbus Pharmaceuticals Holdings negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Corbus Pharmaceuticals Holdings az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Corbus Pharmaceuticals Holdings a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Corbus Pharmaceuticals Holdings által 2024. 10. 02.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 10. 02.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 10. 02. időpontban történt.

2023 évben a Corbus Pharmaceuticals Holdings 0 USD összegű osztalékot fizetett ki.

Az Corbus Pharmaceuticals Holdings osztalékait USD fizeti ki.